Functional constipation is not a disease in the classic sense. It is a functional gastrointestinal disorder, meaning the bowel itself is structurally normal, yet the coordinated mechanics of defecation go awry. Children with the condition pass hard or infrequent stools, strain painfully, and sometimes develop fecal impaction with overflow soiling. The diagnostic gold standards are the Rome III and Rome IV criteria, internationally agreed symptom checklists that allow clinicians to label a child’s constipation as functional rather than caused by anatomic, metabolic, or neurological abnormalities. The distinction matters enormously. Missing an organic cause, such as Hirschsprung disease or hypothyroidism, can be dangerous, while overdiagnosing organic disease in a child who simply needs dietary adjustment leads to unnecessary invasive testing.

Why should a prevalence study of constipation generate excitement? Because the burden is larger than most people appreciate. Untreated functional constipation in childhood is linked to bladder and bowel dysfunction, recurrent urinary tract infections, and behavioral difficulties, and it frequently persists into adolescence and adulthood. Children with chronic constipation report lower quality of life, and parents often underestimate the problem, assuming the child will simply grow out of it. In many Asian healthcare settings, cultural taboos around discussing bowel habits mean families delay seeking help until complications such as painful withholding behavior or encopresis have already taken root. A reliable estimate of how many children are affected is the first step toward allocating clinical resources, training pediatricians, and designing public health messaging.

The research team followed PRISMA guidelines for systematic reviews and prospectively registered their protocol with PROSPERO under registration number CRD420251274382. They searched six major databases, MEDLINE via PubMed, Embase, the Cochrane Central Register of Controlled Trials, LILACS, CNKI, and Ichushi-Web, from inception through December 30, 2025. Crucially, they also combed the grey literature, including conference proceedings, dissertations, and clinical trial registries, which often harbor studies that never reach mainstream journals. To qualify, studies had to be cross-sectional in design, apply Rome III or Rome IV diagnostic criteria, and report functional constipation prevalence in individuals aged zero to eighteen. This methodological rigor matters because prevalence meta-analyses are notoriously vulnerable to cherry-picking and inconsistent case definitions.

For the statistical synthesis, the authors used a random-effects meta-analysis of proportions with logit transformation, the standard technique for combining prevalence estimates that do not follow a normal distribution. Heterogeneity, the statistical term for variability among study results beyond what chance would explain, was quantified with the I-squared statistic and Cochran’s Q test. The pooled prevalence came out at 8 percent, with a 95 percent confidence interval of 5 to 11 percent. But here is the twist that the authors themselves emphasize: the I-squared value was a staggering 99.8 percent, and the 95 percent prediction interval stretched from 1 percent to 25 percent. In plain language, the true prevalence in any given Asian setting could plausibly be anywhere between nearly negligible and one in four children.

That prediction interval is the most scientifically honest part of the paper. A confidence interval tells you about the precision of the average estimate; a prediction interval tells you where a new study’s result would likely fall. When that interval spans nearly the entire plausible range, the pooled 8 percent figure cannot be treated as a precise, generalizable number for the continent. The authors are refreshingly candid about this, warning that the result should be interpreted with caution and highlighting substantial methodological and contextual variability across the included studies. Rather than undermining the work, this transparency strengthens it. Too many meta-analyses present a single tidy number and leave readers unaware that the underlying data are wildly discordant.

The subgroup analyses reveal where that variability comes from. Prevalence was numerically higher in adolescents, at 13 percent, than in young children aged zero to six, at 7 percent, a pattern that may reflect accumulated years of withholding behavior, dietary shifts, and school-related toileting avoidance. Setting mattered too: school-based studies reported 13 percent, compared with just 5 percent in community settings, likely because school surveys capture children whose symptoms are visible in daily routines, while community sampling may undercount or reflect different response patterns. Geography played a role as well, with estimates ranging from 6 percent in Southeast Asia to 10 percent in West Asia. Intriguingly, the choice of diagnostic criteria made almost no difference, with both Rome III and Rome IV studies converging on 10 percent, suggesting the two symptom frameworks identify largely overlapping populations.

The team also stress-tested their result. A leave-one-out sensitivity analysis, in which each study is removed in turn and the pooled estimate recalculated, confirmed that no single study was driving the overall figure. Publication bias assessment was performed to check whether small studies with striking results were disproportionately represented. These checks are the difference between a meta-analysis that merely aggregates numbers and one that earns scientific trust. Still, the extreme heterogeneity signals that future research must move beyond simply counting cases. Standardized diagnostic protocols, consistent age stratification, and geographically diverse sampling frames are needed before the true regional picture of pediatric bowel health in Asia can be drawn with confidence.

What should clinicians and parents take away? First, functional constipation is common enough that pediatricians should screen for it routinely rather than waiting for families to raise the topic. Second, the higher apparent prevalence in school-age children and adolescents suggests that interventions targeting school environments, accessible toilets, adequate drinking water, and time to use them, could have outsized impact. Third, the variation between hospital, community, and school settings is a reminder that where you look shapes what you find, and that hospital-based samples likely overrepresent the more severe end of the spectrum. The authors call for regionally tailored interventions, an acknowledgment that dietary patterns, toilet training customs, and healthcare access differ dramatically from East Asia to West Asia.

The study, funded by the Tianjin Medical University General Hospital Youth Backbone Fund Project, ultimately delivers a dual message. On one hand, it consolidates the best available evidence and gives Asian health systems a defensible baseline: roughly 8 percent of children, with plausible local rates from 1 to 25 percent. On the other hand, it is a masterclass in statistical humility, showing how a single pooled estimate can conceal enormous real-world diversity. For a condition that is cheap to treat when caught early but costly in suffering when ignored, that combination of a solid baseline and an honest accounting of uncertainty is exactly what the field needs to push forward.

Subject of Research: Prevalence of functional constipation among Asian children and adolescents

Article Title: Prevalence of functional constipation in Asian children and adolescents: a systematic review and meta-analysis of cross-sectional studies

Article References: Wu, X., Zhang, G., Ji, F., Fu, H., Ren, B., Guo, Z., & Sun, D. (2026). Prevalence of functional constipation in Asian children and adolescents: a systematic review and meta-analysis of cross-sectional studies. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07716-3

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07716-3

Keywords: functional constipation, pediatrics, adolescents, meta-analysis, prevalence, Rome IV criteria, Asia, cross-sectional studies, gastroenterology, public health, systematic review, child health

The trial, published in the journal Food Science & Nutrition and registered at ClinicalTrials.gov, enrolled 87 adults diagnosed with functional constipation under the Rome IV criteria, the international standard that requires fewer than three spontaneous bowel movements per week or hard Bristol Stool Form Scale types 1 or 2. Participants were randomly assigned in a 1:1 ratio to receive either a daily sachet containing 3 grams of dextrin blended with 3.0 × 10^10 colony-forming units of P. acidilactici PA53, or an identical sachet of dextrin alone. The sachets were indistinguishable in appearance, taste, and packaging, and neither the participants nor the investigators knew who received what until the database was locked. Eighty-one participants completed the full eight-week intervention, with dropout rates evenly spread across the two arms.

The primary endpoint was change in stool consistency as measured by the Bristol Stool Form Scale, a seven-point scale on which types 1 and 2 describe hard, lumpy stools and types 3 and 4 describe the smooth, formed stools considered ideal. After eight weeks, the PA53 group’s average score rose from 1.93 to 2.76, a statistically significant improvement, while the placebo group barely moved from 2.00 to 2.03. At week 8, the between-group difference was significant, with the probiotic group scoring meaningfully higher than the placebo group. The researchers note that although the magnitude of change was modest, a directional shift in stool form is considered clinically meaningful in functional constipation because stool consistency tracks closely with patient-reported comfort, ease of defecation, and perceived bowel regularity.

Bowel movement frequency told a more nuanced story. Within the PA53 group, the proportion of participants reporting four to six spontaneous bowel movements per week rose from seven people at baseline to sixteen at week 8, a within-group improvement that reached statistical significance. However, when the two groups were compared head to head, the difference in frequency did not reach significance. The authors suggest that stool form may simply be more sensitive than evacuation frequency to short-term probiotic intervention, a dissociation that has been reported in earlier constipation research. Quality of life, measured with the PAC-QOL questionnaire, and psychological status, measured with the DASS-21 scale, showed no significant changes in either group.

To probe possible mechanisms, the team measured a panel of gut-related biochemical and immune markers at baseline, week 4, and week 8. These included serotonin, the enteric neurotransmitter that promotes peristalsis; motilin, a hormone that stimulates the migrating motor complexes that sweep contents through the gut; and somatostatin, an inhibitory signal that slows transit. Both groups showed similar temporal trends, with motilin rising and somatostatin falling over time, but no significant between-group differences emerged for any of the three hormones. The researchers are careful to frame these patterns as time-dependent physiological fluctuations rather than confirmed treatment-related neuroendocrine modulation, and they describe any mechanistic interpretation as hypothesis-generating rather than proven.

The inflammatory markers offered a similar picture of suggestive but not conclusive signals. Interleukin-6, a pro-inflammatory cytokine, decreased significantly within the PA53 group over the eight weeks, while the placebo group showed no comparable change, although the between-group difference itself was not significant. Interleukin-10, an anti-inflammatory cytokine, rose significantly within the probiotic group by week 8 relative to baseline. Interleukin-4 levels, which happened to be higher in the probiotic group at baseline, fell in both arms. The authors emphasize that these biomarker changes were primarily within-group temporal patterns and should be read as exploratory signals, not confirmed treatment effects, particularly given the absence of consistent between-group differences across the inflammatory panel.

The microbiome data were among the most technically revealing. Using 16S rRNA gene sequencing of the V3–V4 hypervariable region, with reads processed through USEARCH, clustered into operational taxonomic units at 97 percent similarity, and classified against the SILVA 138 database, the team tracked microbial communities across all three time points. At baseline, the two groups were statistically indistinguishable in both alpha diversity and beta diversity. By week 4, linear discriminant analysis effect size analysis detected significant enrichment of the genus Pediococcus in the probiotic group, evidence that the administered strain was persisting in the gut, and this enrichment persisted at week 8. Meanwhile, overall alpha diversity within the PA53 group declined significantly from baseline to week 8, and phylum-level composition shifted, with Actinomycetota increasing and Synergistota decreasing over time. The placebo group’s microbiota remained essentially static throughout.

The decline in diversity within the treated group is an intriguing wrinkle. Probiotic interventions do not always raise diversity; a single strain can rise to dominance and compress evenness while still producing beneficial functional shifts. Animal studies of P. acidilactici have shown increases in beneficial genera such as Bifidobacterium and Lactobacillus alongside decreases in potentially pathogenic Enterobacteriaceae, changes that can boost short-chain fatty acid production, lower luminal pH, and stimulate peristalsis. PA53 also produces pediocin, a bacteriocin with antimicrobial activity that may help maintain microbial homeostasis. Whether such cascades occurred in these human participants was not directly tested, since short-chain fatty acid levels and mucosal immune markers were not measured, a gap the authors acknowledge.

Safety results were reassuring across the board. Routine laboratory parameters, including albumin, liver enzymes, creatinine, uric acid, urea, and glucose, remained within normal ranges and showed no significant changes or between-group differences at any time point. No serious adverse events were reported, and the supplement was well tolerated, consistent with the safety profiles of other P. acidilactici strains studied in animals and in fermented-food contexts.

The study has honest limitations. The sample size, though larger than the minimum power calculation required, was modest, and the categorical recording of bowel movement frequency may have blunted statistical sensitivity. The eight-week window may have been too short to capture long-term microbial restructuring or the durability of symptom relief. Diet was not strictly controlled, and the dextrin used as placebo is itself a soluble dietary fiber that could exert mild effects on bowel function, which may have actually underestimated the true treatment effect. Still, the trial stands out for integrating clinical, inflammatory, and microbiome endpoints in a rigorously blinded design for a strain that had previously lacked high-quality human evidence. The authors call for larger, multi-center trials with longer follow-up and richer mechanistic measurements, but for now the message is straightforward: a daily sachet of PA53 made stools softer and measurably reshaped the gut ecosystem, offering a promising, strain-specific addition to the probiotic toolkit for functional constipation.

Subject of Research: A randomized controlled trial of Pediococcus acidilactici PA53 probiotic supplementation for functional constipation in adults

Article Title: Pediococcus acidilactici PA53 Supplementation Improves Stool Form and Modulates Gut Microbiota and Inflammatory Responses in Adults With Functional Constipation: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Article References: Xia, Y., Cai, Y., Zhang, Y., Cai, R., Liu, H., & Qiang, Z. (2026). Pediococcus acidilactici PA53 Supplementation Improves Stool Form and Modulates Gut Microbiota and Inflammatory Responses in Adults With Functional Constipation: A Randomized, Double‐Blind, Placebo‐Controlled Trial. Food Science & Nutrition, 14(10), Article e72370. https://doi.org/10.1002/fsn3.72370

Image Credits: AI Generated

DOI: 10.1002/fsn3.72370

Keywords: functional constipation, probiotics, Pediococcus acidilactici, gut microbiota, Bristol Stool Form Scale, randomized controlled trial, inflammatory cytokines, 16S rRNA sequencing, gut-brain axis, microbiome, stool consistency, clinical trial